Parallel Discovery of Alzheimer’s Therapeutics-Reference-Cited by-同舟云学术

Parallel Discovery of Alzheimer’s Therapeutics

Published:2014-06-18 Issue:241 Volume:6 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Lo Andrew W.¹²³,Ho Carole⁴,Cummings Jayna¹,Kosik Kenneth S.⁵

Affiliation:

1. Massachusetts Institute of Technology (MIT) Sloan School of Management and Laboratory for Financial Engineering, Cambridge, MA 02142, USA.

2. MIT Computer Science and Artificial Intelligence Laboratory and Department of Electrical Engineering and Computer Science, Cambridge, MA 02142, USA.

3. AlphaSimplex Group, Cambridge, MA 02142, USA.

4. Early Clinical Development, Genentech, South San Francisco, CA 94080, USA.

5. Neuroscience Research Institute and Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.

Abstract

Government support for parallel development of AD therapeutics.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference33 articles.

1. 2014 Alzheimer's disease facts and figures

2. Pharmaceutical Research and Manufacturers of America (PhRMA) Researching Alzheimer’s Medicines: Setbacks and Stepping Stones (PhRMA Washington DC 2012).

3. Johnson & Johnson “Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimer’s Disease ” published online 06 August 2012.www.investor.jnj.com/releasedetail.cfm?ReleaseID=698466.

4. Eli Lilly “Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer’s Disease ” published online 24 August 2012.http://lilly.mediaroom.com/index.php?s=9042&item=132129.

5. Commercializing biomedical research through securitization techniques

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What will it take to achieve brain health globally?;Cerebral Circulation - Cognition and Behavior;2024

2. Financial intermediation and the funding of biomedical innovation: A review;Journal of Financial Intermediation;2023-04

3. Financing Biomedical Innovation;Annual Review of Financial Economics;2022-11-01

4. The road to precision medicine: Eliminating the “One Size Fits All” approach in Alzheimer’s disease;Biomedicine & Pharmacotherapy;2022-09

5. Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development;Alzheimer's Disease Drug Development;2022-03-31